1. Home >
  2. M&A >
  3. Venture >
  4. United States >
  5. Pennsylvania >
  6. HBM Partners Invests In Galera Therapeutics

Investment Summary

HBM Partners Invests In Galera Therapeutics

On September 19, 2018, private equity firm HBM Partners invested in life science company Galera Therapeutics

Investment Highlights
  • This is HBM Partners’ 17th transaction in the Life Science sector.
  • This is HBM Partners’ 14th transaction in the United States.
  • This is HBM Partners’ 2nd transaction in Pennsylvania.
Investment Fate
  • Galera Therapeutics went public in 2019.

Investment Summary
Date 2018-09-19
Target Galera Therapeutics
Sector Life Science
Investor(s) HBM Partners
Deal Type Venture

Target

Galera Therapeutics

Malvern, Pennsylvania, United States
Galera Therapeutics develops novel therapeutics that reduce severe side effects of radiation therapy in cancer patients. The lead molecule GC4419 has demonstrated efficacy in a phase IIb study in patients with head and neck cancer and has been granted Fast Track and Breakthrough Therapy designations by the U.S. FDA. Galera Therapeutics was founded in 2012 and is based in Malvern, Pennsylvania.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor

HBM Partners

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2001
PE ASSETS 2.1B USD
Size Large
Type Sector Focused
DESCRIPTION

HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.

DEAL STATS #
Overall 22 of 65
Sector: Life Science M&A 17 of 56
Type: Venture M&A Deals 15 of 52
State: Pennsylvania M&A 2 of 4
Country: United States M&A 14 of 44
Year: 2018 M&A 4 of 8
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-09-04 Jianke

Guangzhou, China

Jianke provides online chronic disease management services in China. The company provides services through online chronic disease management platform to address the needs of patients with chronic disease, such as hypertension, cardiovascular and respiratory chronic diseases. Jianke was founded in 2015 and is based in Guangzhou, China.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-09-20 Y-mAbs Therapeutics

Princeton, New Jersey, United States

Y-mAbs Therapeutics is a commercial-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. With a broad and advanced product pipeline, including pivotal-stage product candidates against a range of targets. Y-mAbs Therapeutics was founded in 2015 and is based in Princeton, New Jersey.

Sell -
Mergr

Solution for

Product

Company

Legal